i 1.00 Hours

Course Overview

Research and development of targeted therapies for cancer treatment has dramatically increased in recent years. Several new targeted therapies have been approved by the Food and Drug Administration (FDA) over the past 5 years. Some of the most recently approved small molecule inhibitors include ivosidenib (Tibsovo®) and dacomitinib (Vizimpro®), and new monoclonal antibodies that have reached the market consist of cemiplimab-rwlc (Libtayo®) and mogamulizumab-kpkc (Poteligeo®). These therapies target specific proteins or receptors involved in cancer cell growth, metastasis, and survival. Unlike treatment with chemotherapeutic agents and radiotherapy, which have non-specific mechanisms that lead to widespread systemic toxicity, targeted therapies exclusively affect specific molecular targets. Targeted therapies support a more personalized approach to cancer treatment and can improve efficacy for many types of cancer. These novel therapies also offer prescribers more options for cancer treatment. Because targeted therapies only target specific proteins or receptors, their mechanisms of action and toxicities often do not overlap with traditional therapies or other targeted therapies. This enables these medications to be used in combination with chemotherapy, radiation therapy, and other targeted therapies, which can enhance treatment efficacy. Targeting a variety of pathways and mechanisms can prevent treatment resistance and treat more aggressive types of cancer. While targeted therapies may offer improved efficacy and limit systemic toxicity, they are also associated with numerous adverse events that can sometimes limit treatment.

About the Course Author

Brittani Zurek, PharmD, is a pharmacist and medical writer who graduated from the University at Buffalo School of Pharmacy. Brittani Zurek, PharmD has declared that no conflict of interest, Relevant Financial Relationship or Relevant Non-Financial Relationship exists.

Get started now and your first course is free!

Become a member today and enjoy instant savings on all courses

Accreditation Information

Certificates provided by accrediting body (3 Match)

  • American Society of Radiologic Technologists


    This activity is approved for credit by the American Society of Radiologic Technologists (ASRT) until 11/1/2021.
    Approved by the ASRT for Category A continuing education credit
    This activity may be available in multiple formats or from different sponsors. ASRT regulations state that an individual may not repeat a self-learning activity for credit if it was reported in the same or any subsequent biennium.
  • Accreditation Council for Pharmacy Education


    In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Type Activity: Knowledge
    Target Audience Designation: P
    ACPE Universal Activity Number: JA4008266-0000-21-175-H01-P
  • Mississippi State Department of Health Bureau of Professional Licensure Medical Radiation Technologists


    Mississippi State Department of Health Bureau of Professional Licensure Medical Radiation Technologists (CEBroker Provider #50-290).
    Radiation technologists will receive 1.0 contact hours for participating in this course.

Course Details
  • Course Code:

  • Hours:

  • Type:

    Online Course
  • Release Date:

  • Expiration Date:

  • Learning Objectives:

    Describe the differences between small molecule inhibitors and monoclonal antibodies.; Discuss the mechanisms of targeted therapies and how they treat cancer compared to traditional treatments.; Identify adverse effects and toxicities that can occur with the administration of targeted therapies.; Identify the molecular targets of target therapies.
  • Target Audience:

    The target audience for this course is: Pharmacists; Radiologic Technologists.
  • Course Delivery Method and Format:

    Asynchronous/Online Distance Learning; please see certificate details for specifics on delivery format.
    Relias has a grievance policy in place to facilitate reports of dissatisfaction. Relias will make every effort to resolve each grievance in a mutually satisfactory manner. In order to report a complaint or grievance please contact Relias.
    If you require special accommodations to complete this module, please contact Relias Support by completing the web form (https://www.relias.com/help) or by using the chat functionality.
    All courses offered by Relias, LLC are developed from a foundation of diversity, inclusiveness, and a multicultural perspective. Knowledge, values and awareness related to cultural competency are infused throughout the course content.
    Reference herein to any specific commercial product, process, or service by trade name, trademark, service mark, manufacturer or otherwise does not constitute or imply any endorsement, recommendation, or favoring of, or affiliation with, Relias, LLC.
    All characteristics and organizations referenced in the following training are fictional. Any resemblance to any actual organizations or persons living or dead, is purely coincidental.
    To earn continuing education credit for this course you must achieve a passing score of 80% on the post-test and complete the course evaluation.
  • Accommodations:

    If you require special accommodations to complete this module, please contact Relias Customer Support here.
  • Disclosures:

    Expert Reviewers, Instructors, and Staff Writers disclosures will be listed above after the individuals' biographical paragraph. All other members involved within the planning of this educational activity have declared no conflict of interest exists when planning and developing this course.